Presentations
2015
  • Optimising medication outcomes in the ambulatory healthcare system

    October 2015
    Abu Dhabi, UAE

    An invited presentation at the Ambulatory Healthcare Services International Congress, 2015, on October 9, 2015 by James Stevenson (PharmD, FASHP) Visante president, hospital and health system services practise.

  • How antimicrobial stewardship programmes are changing the game against resistant flora

    October 2015
    International Hospital Federation, 39th World Congress. Chicago, IL USA

    A presentation by Visante senior vice president, clinical effectiveness, John Trowbridge, MD, CPE.

    Despite global concerns on the emergence of untreatable “superbugs,” little progress has been made in implementing operational and professional changes to control resistance development and its remarkable expense (US studies indicate resistant infection costs $18,000-$29,000 per case). This presentation summarises fundamental issues surrounding the antimicrobial resistance threat, and how antimicrobial stewardship programmes (ASPs) change antimicrobial use from a game of roulette, to significant reductions in antimicrobial use, resistance, and cost, while also reducing patient morbidity and mortality.

  • Lessons learned from 25 years of OPAT

    April 2015
    2015 National OPAT Conference, London

    A presentation by Visante senior vice president, clinical effectiveness, John Trowbridge on 13 April, 2015.

  • Update on biologics and the emerging classifications of biosimilars

    March 2015
    American Pharmacists Association Annual Meeting, San Diego, CA

    A presentation by James Stevenson, PharmD, FASHP and Edward Li, PharmD, MPH, BCOP

    A recent forecast estimates that by 2015, six out of the top ten selling drugs will be biologics, indicating that these products will be key drivers of the prescription drug market in the United States. The 2010 Affordable Care Act created a pathway for U.S. Food and Drug Administration approval of biosimilar products. This crucial step is expected to invigorate the biosimilars market, which is expected to shadow the booming biologics market, as patents for these agents begin to expire. This presentation describes how key issues regarding the clinical impact of biosimilar interchangeability are being addressed and how they are expected to impact the practice of pharmacy.